CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis

Felix Fischbach(Universität Hamburg), Nicolaus Kröger(Universität Hamburg), Kristin Rathje(Universität Hamburg), Anita Badbaran(Universität Hamburg), Christoph Heesen(Universität Hamburg), Susanna Carolina Berger(Universität Hamburg), Jens Kühle(University of Basel), Boris Fehse(Universität Hamburg), Johanna Richter(The University of Queensland), Nico Gagelmann(Universität Hamburg), Lena Kristina Pfeffer(Universität Hamburg), Dominic Borie, Stefanie Reinhardt(Universität Hamburg), Francis Ayuk(Universität Hamburg), Johan Seibel(Universität Hamburg), Manuel A. Friese(Universität Hamburg)
Med
March 29, 2024
10.1016/j.medj.2024.03.002
Cited by 161

Related Papers

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
|Science|2022|2k
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
|Nature Medicine|2019|948
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
|Nature Reviews Neurology|2022|809
Exercise in patients with multiple sclerosis
|The Lancet Neurology|2017|455
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
|Haematologica|2019|353